التهاب الفقار اللاصق مع التهاب العنبية الأمامية المتكرر أو أمراض الأمعاء الالتهابية النشطة: العلاج بعد فشل الأجسام المضادة وحيدة النسيلة لعامل نخر الورم

References

DOI: 10.1136/ard-2022-223296

If there is a history of recurrent uveitis or active IBD, preference should be given to a monoclonal antibody against TNF.

In patients with active IBD, IL-17i are contraindicated.

Following a first b/tsDMARD failure, switching to another bDMARD (TNFi or IL-17i) or a JAKi should be considered.

Figure 3 summarises the criteria for continuation, namely that after at least 12 weeks of treatment, the disease activity has substantially decreased, as assessed by the ASDAS clinical important improvement, that is, improvement in ASDAS ≥1.1, together with the positive opinion from the rheumatologist to continue.